Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
-
Published:2019-09
Issue:
Volume:119
Page:1-10
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Eggermont Alexander M.M.,
Chiarion-Sileni Vanna,
Grob Jean-JacquesORCID,
Dummer Reinhard,
Wolchok Jedd D.,
Schmidt Henrik,
Hamid Omid,
Robert Caroline,
Ascierto Paolo AntonioORCID,
Richards Jon M.,
Lebbe Celeste,
Ferraresi Virginia,
Smylie Michael,
Weber Jeffrey S.,
Maio Michele,
Hosein Fareeda,
de Pril Veerle,
Kicinski Michal,
Suciu Stefan,
Testori Alessandro
Funder
Actelion
Agenus
Amgen
Bayer
Bristol-Myers Squibb
Catalym
Celldex
Gilead
GlaxoSmithKline
HalioDx
Incyte
IO Biotech
ISA Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Nektar
Novartis
Pfizer
Polynoma
Regeneron
Sanofi
SkylineDx
BMS
GSK
MSD
Roche
Adaptive Biotech
Advaxis
Apricity
Array BioPharma
Ascentage Pharma
Astellas
BeiGene
Celgene
Chugai
Elucida
Eli Lilly
F-star
Genentech
Imvaq
Janssen
Kleo Pharma
Linneaus
Merck
Neon Therapeutics
Ono
Polaris Pharma
PsiOxus
Puretech
Recepta
Trieza
Sellas Life Sciences
Serametrix
Surface Oncology
Syndax
Esanex
Merck Pharmaceuticals
Pierre Fabre
Array
AstraZeneca
Genmab
Idera
Immunocore
Merck Serono
NewLink Genetics
Sandoz
Sun Pharma
4SC
Subject
Cancer Research,Oncology
Cited by
141 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献